Methods of using dantrolene to treat nerve agent exposure
AssigneeEagle Pharmaceuticals, Inc.
InventorAdrian HEPNER
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.
Claims28
A method of protecting a subject from neural necrosis after the subject has been exposed to a nerve agent comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.
A method of treating a subject exposed to a nerve agent comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.
A method of protecting a subject from a decrease in central nervous system function resulting from exposure to a nerve agent comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.
A method of treating nerve agent-induced seizures, in particular status epilepticus, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.
A method of protecting a subject from a central nervous system dysfunction resulting from exposure to a nerve agent comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.
A method of treating behavioral changes resulting from exposure to a nerve agent comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.